The biosimilars segment, too, will see fresh launches including Bevacizumab in the US, and Semaglutide filings across developed and emerging markets, including India by calendar 2026.

The company also reported consolidated revenue of Rs 4,454 crore, reflecting a 15% year-on-year increase on a like-for-like ...

Biocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% to Rs 4,454 crore.

Aviations stocks: Shares of Interglobe Aviation Ltd, the parent company of India's largest airline IndiGo, and SpiceJet will ...

Among many, companies like Ceigall India, Andhra Paper, DB Corp, and Muthoot Microfin also declard their Q4 results today.

Biotech firm Biocon on Thursday said its consolidated net profit surged over two-fold to Rs 344 crore in the fourth quarter ...

Indian biopharma firm Biocon's profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar drugs in its key U.S. and European markets.

Today, companies across sectors including Titan Company, L&T, Pidilite Industries, Asian Paints, Britannia Industries, Canara ...

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara ...

Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of ...

Biocon Biologics secures market access for Yesintek in the US driven by demand from national and commercial formularies: Our Bureau, Bengaluru Monday, May 5, 2025, 12:15 Hrs [IST] ...